Respiratory symptoms do not reflect functional impairment in early CF lung disease. by Korten, Insa et al.
ARTICLE IN PRESS 
JID: JCF [m5G; June 1, 2021;12:29 ] 
Journal of Cystic Fibrosis xxx (xxxx) xxx 
Contents lists available at ScienceDirect 
Journal of Cystic Fibrosis 
journal homepage: www.elsevier.com/locate/jcf 
Respiratory symptoms do not reflect functional impairment in early 
CF lung disease 
Insa Korten a , Marc-Alexander Oestreich a , b , Urs Frey c , Alexander Moeller d , Andreas Jung d , 
Renate Spinas d , Dominik Mueller-Suter e , Daniel Trachsel c , Isabelle Rochat f , Ben Spycher g , 
Philipp Latzin a , Carmen Casaulta a , Kathryn Ramsey a , ∗, for the SCILD, and BILD, study 
group 1 , 2 
a Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern Unviersity Hospital, University of Bern, Switzerland 
b Graduate School for Health Sciences, University of Bern, Switzerland 
c University of Basel Children’s Hospital (UKBB), Basel, Switzerland 
d Division of Respiratory Medicine, University Children’s Hospital Zurich, Switzerland 
e Division of Respiratory Medicine, Children’s Hospital Aarau, Switzerland 
f Department of Paediatrics, Respiratory Unit, Lausanne University Hospital, Lausanne, Switzerland 
g Institute for Social and Preventive Medicine, University of Bern, Switzerland 
a r t i c l e i n f o 
Article history: 
Received 6 December 2020 
Revised 11 April 2021 
Accepted 12 April 2021 







a b s t r a c t 
Background: Lung disease can develop within the first year of life in infants with cystic fibrosis (CF). 
However, the frequency and severity of respiratory symptoms in infancy are not known. 
Methods: We assessed respiratory symptoms in 50 infants with CF and 50 healthy matched controls 
from two prospective birth cohort studies. Respiratory symptoms and respiratory rate were documented 
by standardized weekly interviews throughout the first year. Infants performed multiple breath washout 
in the first weeks of life. 
Results: We analyzed 4552 data points (2217 in CF). Respiratory symptoms (either mild or severe) were 
not more frequent in infants with CF (OR:1.1;95% CI:[0.76, 1.59]; p = 0.6). Higher lung clearance index and 
higher respiratory rate in infants with CF were not associated with respiratory symptoms. 
Conclusions: We found no difference in respiratory symptoms between healthy and CF infants. These data 
indicate that early CF lung disease may not be captured by clinical presentation alone. 
© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. 
This is an open access article under the CC BY-NC-ND license 
















∗ Corresponding author at: Paediatric Respiratory Medicine, University Children’s 
ospital of Bern, University of Bern, Switzerland. 
E-mail address: Kathryn.ramsey@extern.insel.ch (K. Ramsey). 
1 Swiss Cystic Fibrosis Infant Lung Development (SCILD) cohort, current study 
roup: Juerg Barben, MD, St. Gallen; Sylvain Blanchon, MD, Lausanne; Carmen 
asaulta, MD, Bern; Andreas Hector, MD, Zurich; Andreas Jung, MD, Zurich; Elis- 
beth Kieninger, MD, PhD, Bern; Insa Korten, MD, Bern; Philipp Latzin, MD, 
hD, Bern; Alexander Moeller, MD, Zurich; Anne Mornand, MD, Geneva; Dominik 
ueller-Suter, MD, Aarau; Kathryn Ramsey, PhD, Bern; Nicolas Regamey, MD, 
ucerne; Isabelle Rochat MD, Lausanne; Tina Schürmann, MD, Zurich; Florian Singer, 
D, PhD, Bern; Renate Spinas, MD, Zurich; Daniel Trachsel, MD, Basel; Sophie Yam- 
ine, MD, PhD, Bern; Maura Zanolari, MD, Bellinzona. 
2 Basel Bern Infant Lung Development (BILD) cohort, current study group: Fabi- 
nne Decrue, MD, Basel; Urs Frey, MD, PhD, Basel; Oliver Fuchs, MD, PhD, Bern; 
manda Gisler, MD, Basel; Olga Gorlanova, MD, Basel; Claudia E Kuehni, MD, PhD, 














569-1993/© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Cystic
 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Please cite this article as: I. Korten, M.-A. Oestreich, U. Frey et al., Res
CF lung disease, Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2. Introduction 
The introduction of newborn screening (NBS) for cystic fibro- 
is (CF) has allowed for diagnosis shortly after birth and access to 
pecialized treatment [ 1 , 2 ]. Neutrophil inflammation, bacterial col- 
nization and structural damage can occur within the first year of 
ife in children with CF [3–5] , and these early events are associ- 
ted with lung function decline and respiratory morbidity later in 
ife [ 6 , 7 ]. While these early manifestations of lung disease can be
etected in asymptomatic infants with CF, they are more likely to 
ccur in infants with respiratory symptoms [8] . arc-Alexander Oestreich, MD, Bern; Yasmin Salem Mahmoud, MD, Bern; Andras 
oti, MD, Bern; Jakob Usemann, MD, PhD, Basel; Corin Willers, MD, Bern; Sophie 
ammine, MD, PhD, Bern 
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Respiratory symptoms in infants with CF have been associated 
ith impaired lung function outcomes at preschool age [9] . How- 
ver, the frequency and severity of respiratory symptoms in CF 
uring the first year of life have not been investigated systemat- 
cally. While several studies have examined respiratory symptoms 
nd the risk factors for respiratory infections in healthy infants, 
here are limited data in infants with CF [10–13] . Most of our 
nowledge in individuals with CF is drawn from periods of pul- 
onary exacerbations in older children and adults [ 9 , 14 ]. There- 
ore, it is not known whether infants with CF develop more respi- 
atory symptoms than healthy controls over the first year of life. 
In the longitudinal Swiss CF Infant Lung-Development (SCILD) 
ohort, we have previously shown that lung function outcomes, 
espiratory rate, and microbiota composition differ between infants 
ith CF and healthy infants, whereas the number of symptomatic 
espiratory viral infections were similar over the first year of life 
15–19] . In this study we aimed to i) prospectively assess the num- 
er and severity of respiratory symptoms in the first year of life 
n infants with CF compared with healthy controls, ii) determine 
hether infant lung function outcomes are associated with subse- 
uent respiratory symptoms in infants with CF, and iii) to identify 
otential risk factors for respiratory symptoms in early CF disease. 
. Methods 
.1. Study design and population 
In this prospective study, we enrolled infants with CF from the 
wiss CF Infant Lung-Development (SCILD) cohort [20] and healthy 
nfants from the Basel-Bern Infant Lung Development (BILD) cohort 
21] ( www.scild.ch and www.bild-cohort.ch ). Infants born between 
011 and 2016, who had at least 40 weeks of longitudinal surveil- 
ance were included. All infants with CF were diagnosed follow- 
ng NBS and thus most did not present with respiratory symptoms 
rior to study enrollment. Healthy controls were matched accord- 
ng to season of birth, sex, having siblings or not, and attendance at 
hildcare (none of the CF infants or healthy infants in our study at- 
ended childcare). Detailed inclusion and exclusion criteria are re- 
orted in the supplementary material, characteristics of the study 
opulation are displayed in Table 1 . 
At the baseline study visit, at age four to thirteen weeks, we 
ssessed pre- and perinatal information through a standardized in- 
erview with the parent and performed infant lung function test- 
ng. During the first year of life, the child’s health status, antibi- 
tic treatment, respiratory symptoms and respiratory rate were 
rospectively assessed by standardized weekly telephone inter- 
iews [21] (see below). The study was performed in the University 
hildren’s Hospital of Bern, University of Bern, Switzerland and ap- 
roved by the Ethics committee Bern, Switzerland. Informed writ- 
en consent was obtained from all parents. 
.2. Respiratory symptoms 
Symptoms of lower and upper respiratory tract infections, 
heeze and/or cough were recorded in standardized weekly tele- 
hone interviews conducted by a study nurse [21] . Based on re- 
orted symptoms, we calculated a symptom score with a high sen- 
itivity for lower respiratory-tract infections (LRTIs) [22] , ranging 
rom 0 (no symptoms) to 4 (severe respiratory symptoms). The 
coring system has been previously used to investigate respira- 
ory symptoms in infants by others and us [21–23] . For details on 
he symptom score, see Table E1 in the supplement. Furthermore, 
e defined LRTIs as cough, wheeze and/or breathing difficulties in 
ombination with upper respiratory tract symptoms or fever for 
ore than two consecutive days. For data analysis, we classified 2 espiratory health in a given week as (i) free of respiratory symp- 
oms, (ii) mild to moderate respiratory symptoms (symptom score 
 0 and < 3, but no LRTI) and (iii) severe respiratory symptoms 
LRTI and/or symptom score ≥ 3). 
.3. Infant lung function and respiratory rate measurements 
Infant lung function using the multiple breath washout tech- 
ique was assessed in natural quiet sleep according to current 
uidelines [24–26] . Multiple breath washout (MBW) technique was 
erformed using 4% sulfur hexafluoride (SF 6 ) as the inert tracer 
as. The main outcome parameters were the functional residual 
apacity (FRC) and lung clearance index (LCI 2.5% ) [15] . Infant lung 
unction and respiratory rate data in these cohorts have been pub- 
ished previously and therefore details on the methods are de- 
cribed elsewere [ 15 , 17 , 25 , 26 ] and in the supplementary material.
ung function measurements were feasible in all but 15 CF patients 
nd 6 healthy infants, which had to be excluded due to low qual- 
ty of measurements. Parents measured respiratory rate weekly at 
ome, after being instructed by a study nurse how to perform a 
orrect measurement. We obtained data from 42 CF and 34 healthy 
nfants, as participation in this part of study was optional. 
.4. Statistical analysis 
First, we described the distribution (median (minimum – max- 
mum)) of respiratory symptoms ((i) any (ii) mild and (iii) se- 
ere) among infants with CF and healthy infants in the first year 
f life. We than compared weeks with symptoms with CF status 
CF/healthy) as exposure variable, fitting a multilevel logistic re- 
ression model, using a random effect to correct for correlation be- 
ween multiple measurements in the same individual. In an addi- 
ional model we compared the total number of weeks with symp- 
oms in the first year of life between CF and healthy infants us- 
ng Poisson regression models. To identify potential determinants 
or respiratory symptoms in infants with CF, we included the fol- 
owing potential predictors: sex; gestational age (linear in weeks), 
eight at birth (linear in kg); CFTR mutation (residual CFTR func- 
ion yes/no); breastfeeding (yes/no); older siblings (yes/no); mater- 
al smoking in pregnancy (yes/no), mode of delivery (vaginal or 
-section), parental education (low/middle/high), maternal atopy 
yes/no), LCI (linear in lung turnover), FRC (linear in ml/kg), age 
younger/older 6 months) and season. We fitted univariable and 
ultivariable (all selected variables) multilevel logistic regression 
odels. All variables that had a p-value ≤0.1 (likelihood ratio test) 
n one or both of the multivariable models were included in the 
djusted model for our primary aim (CF status as exposure of in- 
erest). 
To investigate associations between respiratory rate and respi- 
atory symptoms in CF infants, we chose respiratory rate measure- 
ent as outcome of interest and included the following possible 
redictors: respiratory symptoms (at week of measurement), res- 
iratory symptoms in weeks per year (in quartiles, from no (1) 
o frequent weeks (4) with respiratory symptoms, siblings, season 
nd age. Upper limit of normal (ULN) for LCI and FRC values were 
efined as mean + 1.64 ∗SD (ULN90%) based on lung function data 
rom the healthy infants from the BILD cohort in this study. Details 
f statistical analyses and power calculation can be found in the 
upplementary material. Statistical analyses were performed using 
tata TM (Stata Statistical Software: Release 13. College Station, TX: 
tataCorp LP), figures were generated using GraphPad Prism 5. 
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Table 1 
Demographics and Baseline Characteristics of Study Population. 
CF (n = 50) Healthy (n = 50) 
Anthropometrics Sex (m) 26 (53) 27 (52) 
Gestational age at birth (weeks) ∗ 39.1 (1.5) 39.5 (1.5) 
Length at birth (cm) ∗ 48.9 (1.7) 49.2 (2.3) 
Birth weight (kg) ∗ 3.2 (0.4) 3.3 (0.5) 
CFTR mutation ‡ No residual CFTR function (pancreatic insufficiency) 44 (88) 
Residual CFTR function (pancreatic sufficiency) 6 (12) 
Nutrition Breastfeeding (Bf) ∗∗ 41 (82) 50 (97) 
Duration of Bf in months ∗ 6.9 (4.1) 7.7 (3.1) 
Environment Siblings: 0 25 (50) 25 (50) 
1 17 (34) 15 (30) 
≥ 2 8 (16) 10 (20) 
Smoking in pregnancy 5 (10) 1 (4) 
Cesarean section 14 (28) 11 (22) 
Maternal atopy 11 (22) 10 (20) 
Parental education ‡‡ Low 19 (38) 17 (34) 
Middle 18 (36) 20 (40) 
High 13 (26) 13 (26) 
Lung function” measurements Lung Clearance Index (lung volume turnover) 7.6 (0.9) 7.5 (0.6) 
Functional Residual Capacity (ml/per kg) 25.0 (4.5) 21.8 (3.2) 
Respiratory symptoms † No. weeks assessed || 45 (40 – 46) 45 (43-46) 
Weeks (%) with respiratory symptoms ∗∗ 15 (0 –71) 16 (0 –44) 
Weeks (%) with mild respiratory symptoms †† 13 (0 – 56) 11 (0 – 38) 
No. of weeks (%) with severe respiratory symptoms ††† 2 (0 – 20) 2 (0 – 11) 
Respiratory rate Baseline measurement at first study visit per min 41 (9.5) 35 (5.7) 
Results are displayed in numbers (%) if not stated otherwise. 
“Lung function measurements included lung clearance index (LCI) and functional residual capacity (FRC) at first study visit. 
∗ Results are displayed as mean (SD). 
† Results are displayed as median (range). 
‡ CF infants were grouped into (i) no residual CFTR function (pancreatic insufficient)), (ii) residual CFTR function (pancreatic 
suffient). 
∗∗ breastfeeding referred to total amount of time and not to episode exclusively breastfed. 
‡‡ Parental education is categorized into low (less than four years of apprenticeship), middle (at least four years of apprentice- 
ship), and high (tertiary education). 
|| Number of weeks in the first year of life per infant, during which respiratory symptoms were measured. 
∗∗ Number of weeks in the first year of life, during which respiratory symptoms were recorded. 
†† Number of weeks in the first year of life, during which mild to moderate respiratory symptoms were recorded (symptom 
score > 0 and < 3, no lower respiratory tract infection (LRTI)). 

















































.1. Study population 
We included 50 infants with CF and 50 healthy infants in our 
tudy, resulting in 2217 data points in CF and in 2235 data points 
n healthy infants. Details on anthropometrics, environmental or 
utritional status can be found in Table 1 . The mean (SD) age at
tudy inclusion was 9.0 (1.7) weeks for CF and 8.0 (0.0) weeks for 
ealthy infants. The median (min-max) number of recorded weeks 
f surveillance per infant was 45 (40-46) weeks in CF and 45 (43 
46) weeks in healthy infants. There were no significant differ- 
nces in anthropometrics, environmental or nutritional status in 
nfants with CF compared to healthy controls, except that infants 
ith CF were slightly older when included in the study (1.8 and 
.1 months, respectively, p < 0.001). 
.2. Differences in respiratory symptoms between infants with CF and 
ealthy infants 
Respiratory symptoms were recorded in 7 (median; range 0 - 
2) weeks in CF and 7 (0 – 20) weeks in healthy infants. Symp- 
oms were mild to moderate in 6 (0-25) and 5 (0 – 15) weeks, and
evere in 1 (0 – 9) and 1 (0 – 5) weeks in CF and healthy infants,
espectively. 
We compared respiratory symptoms between infants with CF 
nd healthy infants throughout the first year of life using multi- 
evel regression models. The number of weeks with any respiratory 3 ymptoms (mild or severe) did not differ between CF and healthy 
n the univariable model (results not shown) or after adjustment 
or possible effect modifiers (age, season, having siblings, details in 
able 2 , Table E2, Fig. 1 ). CF infants were more likely to be treated
ith antibiotics during episodes with severe respiratory symptoms 
43 vs. 16 weeks, OR: 4.0, 95% CI: 1.94 – 9.35, p < 0.001). In a sen-
itivity analysis, taking the total number of weeks with symptoms 
er infant as the outcome in a Poisson regression analysis, we 
ound no difference between healthy and CF infants (IRR: 1.1, 95% 
I: 0.93.– 1.24; p = 0.34). In addition, duration of respiratory symp- 
oms (counting the consecutive weeks with respiratory symptoms) 
as not different between CF and healthy infants (IRR: 1.12, 95% 
I: 0.94 – 1.34; p = 0.2). Due to low numbers, we could not assess 
hether infants with more frequent respiratory symptoms in the 
rst six months of life were at a higher risk for more respiratory 
ymptoms in the subsequent six months ( Fig. 2 ). Details on spe- 
ific respiratory symptoms can be found in the supplement Table 
3 and E4. 
.3. Risk factors for respiratory symptoms in infants with CF 
We investigated possible predictors for respiratory symptoms 
or CF infants. In the univariable model, we found that those with 
ore weeks of respiratory symptoms were older and had siblings. 
nfants with CF had less frequent respiratory symptoms during 
eeks of breastfeeding and during summer (details are provided 
n Table E5). The association between respiratory symptoms and 
reastfeeding was likely confounded by age, as no effect was seen 
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Table 2 
Differences in respiratory symptoms between healthy and CF infants. 
Multivariable model 
Variable + Category OR 95% CI p-value †† (LR- test) 
Respiratory symptoms CF status ∗ Healthy 1 [1.00,1.00] 0.6 
CF 1.1 [0.76,1.59] 
Siblings ‡ No 1 [1.00,1.00] < 0.001 
Yes 2.17 [1.50,3.14] 
Age † 0-6 m 1 [1.00,1.00] < 0.001 
6-12 m 1.68 [1.40,2.01] 
Season †† Summer 1 [1.00,1.00] < 0.001 
Spring 1.69 [1.30,2.21] 
Fall 2.00 [1.54,2.59] 
Winter 2.40 [1.86,3.10] 
Severe respiratory symptoms CF status ∗ Healthy 1 [1.00,1.00] 0.45 
CF 1.19 [0.75,1.89] 
Siblings ‡ No 1 [1.00,1.00] < 0.001 
Yes 2.79 [1.71,4.54] 
Age † 0-6 m 1 [1.00,1.00] 0.001 
6-12 m 1.85 [1.26,2.73] 
Season †† Summer 1 [1.00,1.00] < 0.001 
Spring 1.90 [1.07,3.39] 
Fall 1.68 [0.93,3.03] 
Winter 3.17 [1.96,3.10] 
Logistic regression models investigating differences in respiratory symptoms and severe respiratory 
symptoms (outcome variables) between healthy and CF infants in a multivariable model adjusted for 
siblings, age and season. 
OR: Odd ratio, CI: Confidence Interval 
†† p-value: from likelihood ratio test. 
+ all variables are included in the same model, displayed is the result for each variable (as exposure 
to respiratory symptoms) in the adjusted model. 
∗ The reference category are healthy infants. 
† Age displayed in two groups: the reference category is age below 6 months (m). 
‡ The reference category are infants with no siblings. 
†† Season is divided in the calendric seasons. The reference category is summer. 
Fig. 1. a: Percentage of weeks with respiratory symptoms per infant in the first year of life. Displayed are all symptoms (light grey) and severe symptoms (dark grey) for 
healthy and CF infants. Fig. 1 b: Number of weeks with severe respiratory symptoms in healthy and CF infants younger and older than 6 months of age. The colored symbols 



























hen age was included in the analysis (detailed results are pro- 
ided in the supplement). Similar results were found when we as- 
essed only mild or severe symptoms (results not shown) and in 
he multivariable analyses (adjusted for age, season and siblings) 
 Table 3 ). We found no association between respiratory symptoms 
nd any of the other variables: sex, gestational age, weight at birth, 
moking in pregnancy, mode of delivery, maternal atopy, parental 
ducation, LCI and FRC measurements (univariable analyses are 
isplayed in Table E5 in the supplementary material). 
.4. Infant lung function measurement and respiratory symptoms 
In infants with CF, no linear association was found between 
requency of respiratory symptoms and LCI or FRC (Coeff: 1.06, 
I:[0.72,1.55]; p = 0.8 and 0.99; 95% CI: [0.92,1.07]; p = 0.9, respec- 4 ively). Four infants with CF had LCI values above the ULN and 
leven infants FRC values above the ULN. Values above the ULN 
ere not associated with more severe respiratory symptoms (re- 
ults not shown); however, numbers were too low for sufficient 
tatistical analysis ( Fig. 2 a and b). We thus performed two addi- 
ional sensitivity analyses, grouping the infants into infants with 
CI < 7.4 and > 7.4 (below and above the 50 th percentile) and 
nto infants with LCI < 8.0 and > = 8.0 (below and above the 75 th 
ercentile). Results showed no associations between lung function 
utcomes and any, severe or mild symptoms in both analyses (re- 
ults not shown). 
We found that respiratory rate was transiently elevated dur- 
ng periods with severe respiratory symptoms (Coef 3.0; 95% CI: 
1.50, 4.58]; p = < 0.001) and in infants with impaired lung function 
hortly after birth (FRC: Coef -0.42; 95% CI: [-0.78, -0.07]; p = 0.02, 
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Fig. 1. Continued 
Table 3 
Predictors for respiratory symptoms in infants with cystic fibrosis. 
Variable Category OR 95% CI p-value †† (LR-test) 
Respiratory symptoms Siblings ‡ No 1 [1.00,1.00] 0.011 
Yes 2.05 [1.18,3.55] 
Age § 0-6 m 1 [1.00,1.00] 0.021 
6-12 m 1.34 [1.04,1.71] 
Season ††† Summer 1 [1.00,1.00] 0.006 
Spring 1.45 [1.02,2.08] 
Fall 1.68 [1.19,2.37] 
Winter 1.74 [1.23,2.46] 
Severe respiratory symptoms Siblings ‡ No 1 [1.00,1.00] 0.013 
Yes 2.62 [1.23,5.59] 
Age § 0-6 m 1 [1.00,1.00] 0.24 
6-12 m 1.35 [0.82,2.22] 
Season ††† Summer 1 [1.00,1.00] 0.02 
Spring 1.81 [0.82,3.99] 
Fall 2.25 [1.04,4.85] 
Winter 2.93 [0.96,2.02] 
Mild to moderate respiratory symptoms Siblings ‡ No 1 [1.00,1.00] 0.04 
Yes 1.75 [1.03,2.95] 
Age § 0-6 m 1 [1.00,1.00] 0.06 
6-12 m 1.29 [0.99,1.68] 
Season ††† Summer 1 [1.00,1.00] 0.2 
Spring 1.34 [0.92,1.96] 
Fall 1.49 [1.03,2.14] 
Winter 1.40 [0.96,2.02] 
Possible predictors for respiratory symptoms in infants with CF and healthy infants. Displayed are only results from 
the multivariable model (all variables listed above in the same model). 
OR.: Odds ratio, CI: Confidence Interval 
‡ The reference category are infants without siblings. 
§ Age displayed in 2 groups; the reference category is age below 6 months (m). 
††† season is divided in the calendric seasons. The reference category is summer. 



























or detailed results see Table E6 in the supplementary material). 
owever, when we grouped the infants from less to more frequent 
espiratory symptoms in the first year (in quartiles), respiratory 
ate was not different between the four groups (highest quartile: 
oef 0.58; 95% CI: [-4.33, 5.49]; p = 0.5), for detailed results see 
able E6 in the supplementary material). Therefore, infants with 
ore frequent respiratory symptoms did not have a higher respira- 
ory rate over the first year of life (s. Figure E1 in the supplement)
We could not obtain acceptable lung function data and respi- 
atory rate measurements in a small group of infants (for details 
ee methods section). Thus, to confirm our results we compared 
hese infants with the infants who completed all measurements. 
e found no differences in baseline characteristics, frequency and 
everity of respiratory symptoms in infants without lung function 
ata or respiratory rate measurements. 5 . Discussion 
Respiratory symptoms were not more frequent in the first year 
f life in infants with CF compared to healthy controls in this 
rospective, observational study. In infants with CF, the frequency 
f respiratory symptoms increased with increasing age, depended 
n season, and symptoms were more frequent in infants with older 
iblings. In infants with CF, baseline LCI and FRC were not associ- 
ted with subsequent respiratory symptoms, and those with more 
requent respiratory symptoms in the first year of life did not have 
 higher respiratory rate. The lack of association between respira- 
ory symptoms and early lung function or respiratory rate mea- 
urements indicates that early lung disease might not be captured 
y the clinical presentation in infants with CF. 
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Fig. 2. a: Association of LCI 2.5% and consecutive weeks with severe respiratory 
symptoms in infants with CF within the first year of life. Each symbol represents 
one infant with CF. The dashed line is the ULN (LCI 2.5% 8.5). Fig. 2 b: Association FRC 
(ml/kg) and consecutive weeks with severe respiratory symptoms in infants with CF 
within the first year of life. Each symbol represents one infant with CF. The dashed 
line is the ULN (FRC ml/kg 27.06). 



















































































.1. Comparison with literature 
This is the first study to compare weekly respiratory symptoms 
ata between infants with CF and healthy controls in the first year 
f life using standardized questionnaires. We found that infants 
ith CF have a median of 1 week with severe and 7 weeks with
ny respiratory symptoms in the first year of life. A study of chil- 
ren with CF aged 0-5 years reported a mean of 3.66 pulmonary 
xacerbations per person year, with higher numbers of exacerba- 
ions reported in toddlers and preschool children [9] . In the age 
roup 0-1 year the authors reported 284 exacerbations in 168 chil- 
ren. Another study of young children with CF reported an average 
f 2.3 exacerbations per year, however the mean (SD) age of these 
hildren (2.3 (1.5) years) were older than in our study [27] . The 
RESIS trial [28] reported an exacerbation rate of 1.1 (with regular 
ypertonic saline inhalation) and 1.2 (with regular isotonic saline 
nhalation) in infants with CF within the first year of life. These 
umbers are similar to our results. As we did not assess clini- 
ian defined exacerbations, but rather the number of weeks with 
arentally reported symptoms, it is not possible to directly com- 
are these numbers. 
In our study, infants with CF did not have more frequent or se- 
ere respiratory symptoms in the first year of life than healthy in- 
ants. We found no comparable studies that have examined respi- 
atory symptoms in infants with CF and healthy controls over the 6 rst year of life. Several studies have reported more frequent or 
evere respiratory symptoms in older children with CF compared 
o healthy controls [29] . One of these studies reported a similar 
requency of acute respiratory illnesses in children with CF and 
ealthy children, but they found longer periods of lower respira- 
ory tract symptoms in the CF group [30] . 
We found that age, season, and siblings were predictors for res- 
iratory symptoms in infants with CF. These predictors have pre- 
iously been reported to be associated with respiratory symptoms 
n healthy infants by others and us [ 13 , 31–33 ]. An increased expo-
ure to respiratory pathogens in children with older siblings (pos- 
ibly attending childcare), with increasing age (increasing contact 
o other individuals and environment) and in winter (where res- 
iratory viruses have their peak season) can explain these results 
n healthy and CF infants. As none of the infants in this study 
ttended childcare, an important risk factor for airway infection 
ould be excluded. The number of respiratory exacerbations has 
reviously been shown to increase with age in children with CF 
9] . Progression of lung damage and more frequent infections may 
esult in more frequent respiratory symptoms with increasing age 
34] . 
Lung function and respiratory rate were not associated with 
espiratory symptoms in our study. Lung function measurements 
ere performed within the first weeks of life when infants were 
ostly asymptomatic. Infants with CF have been shown to have 
mpaired lung function in the first year of life without overt res- 
iratory symptoms [ 3 , 35 ]. Other studies have reported associations 
etween respiratory symptoms and lung function outcomes during 
eriods of pulmonary exacerbation in toddlers [31] , school aged 
hildren, and adults with CF [36] . In toddlers and children, elevated 
CI measurements, as well as ventilation and perfusion defects in 
agnetic resonance imaging (MRI), were reported in clinical sta- 
le patients and during exacerbations. While a strong association 
ould be found between LCI and MRI, several patients had normal 
CI values despite impaired MRI outcomes [37–39] . These data in- 
icate that while LCI is a sensitive marker of early lung disease, it 
oes not over-estimate the level of impairment. 
We have previously shown that respiratory rate is higher in in- 
ants with CF compared with healthy infants in the first year of 
ife and is transiently elevated during periods of severe respiratory 
ymptoms in healthy and CF infants [17] . In the current study, we 
ould reproduce these results with elevated respiratory rate dur- 
ng periods with respiratory symptoms. However, we found that 
levated respiratory rate (weekly measurements investigating “in- 
ividual baseline respiratory rate”) in the first year of life was not 
ssociated with a higher number of respiratory symptoms in in- 
ants with CF. 
.2. Clinical implications 
Due to early diagnosis following newborn screening, all infants 
ith CF in our cohort received medical care in a specialized CF 
enter shortly after birth. In Switzerland, most infants with CF 
eceive regular inhalation therapy; however, treatment can differ 
lightly between CF centers. We did not collect detailed informa- 
ion on inhalation therapy in this study. Infants with CF were more 
ikely to receive antibiotic treatment during periods of respiratory 
ymptoms compared to healthy controls. These precautionary mea- 
ures are likely to influence respiratory outcomes in infants with 
F. Only a small number (not statistically significant, but graphi- 
ally visualized in Fig. 1 a and b) presented as severely clinical ill 
t the beginning of life. The number of weeks with respiratory 
ymptoms was not associated with early lung function measure- 
ents. This could suggest that lung function deficits are transient 
40] , however it could also indicate that early sub-clinical changes 
annot be captured by the clinical presentation of the disease. The 
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atter hypothesis is supported by bronchioalveolar lavage studies 
hich show that bacterial pathogens and markers of neutrophil 
nflammation were detected in the lungs of asymptomatic infants 
ith CF [ 3 , 8 , 41 ]. Furthermore, we have previously shown that res-
iratory rate is consistently higher in infants with CF in the first 
ear of life compared to healthy controls, which suggests the pres- 
nce of early lung damage [17] . 
.3. Strengths and limitations 
A unique feature of our study is the longitudinal prospective 
tudy design with weekly follow-up throughout infancy. Respira- 
ory symptoms were documented using a standardized symptom 
core. The BILD healthy infant cohort allowed us to directly com- 
are the number of respiratory symptoms between infants with 
F and contemporary healthy controls. Infant lung function and 
espiratory rate measurements were performed which allowed us 
o discriminate between clinical or subclinical changes. We evalu- 
ted parentally reported respiratory symptoms in our study but did 
ot assess clinician-defined exacerbations. The focus of our study 
as to compare the frequency and duration of weekly respiratory 
ymptoms between infants with CF and healthy infants. In order to 
educe recall bias, experienced study nurses performed standard- 
zed interviews each week using a validated questionnaire. We re- 
uested information on antibiotic therapy, which can be used as 
 proxy for exacerbations, but did not assess any other clinical 
are or treatments in this multicenter study. It is likely that clinical 
reatment differed between centers and this may have influenced 
espiratory symptoms in the CF population. It is also possible that 
nfants with CF who had higher LCI measurements received inten- 
ified treatment in some centers. These measures of precaution in 
F infants might contribute to our results. A further limitation of 
he study is that lung function was only analyzed cross-sectionally 
nd lung function outcomes may change throughout infancy [40] . 
uture studies investigating the course of lung function longitudi- 
ally in CF infants are required to determine whether early im- 
airments is transient or track through childhood. Environmental 
moking was not included as a confounder because there was a 
arge overlap with smoking in pregnancy, the numbers were low, 
nd there was no indoor smoking reported. Also, in this study we 
ere not able to determine whether respiratory symptoms were 
aused by viral or bacterial infections or other causes. A further 
imitation of our study is the relatively small sample size of our 
tudy population. Sample size estimation was based on clinical 
onsiderations. If no difference in symptom frequency is detectable 
n groups of 50 patients, likely no clinically relevant consequences 
ill be required. However, we cannot reject the hypothesis, that 
mall differences in symptom patterns, further differences and/or 
dditional risk factors are potentially detectable in very large epi- 
emiological cohorts. 
. Conclusion 
In conclusion, we found no difference in respiratory symptoms 
etween infants with CF and healthy infants in the first year of 
ife. The lack of association may be explained by the mild disease, 
arly interventions (more frequent antibiotic therapy, regular in- 
alation therapy), and precautionary measures taken (e.g. not at- 
ending childcare) in our cohort of infants with CF diagnosed fol- 
owing NBS. Impaired lung function and respiratory rate outcomes 
n infants with CF were not associated with respiratory symptoms. 
he fact that CF infants do not show elevated symptoms in the 
rst year of life indicates that early subclinical changes might not 
e captured by the clinical presentation of patients. Our findings 
upport the assessment of early CF disease with sensitive measure- 
ents like MRI or MBW to capture earliest lung damage. 7 unding 
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